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The pancreatic ductal adenocarcinoma (PDAC) microenvironment accommodates a variety
of cell types and a plethora of complex interactions between tumor cells, host cells
and extracellular matrix (ECM) components. Here we review the role of inflammatory
cells, in particular mast cells, myeloid-derived suppressor cells, macrophages, T
regulatory cells, T helper cells and neutrophils. The picture that emerges is that of a
tumor microenvironment, in which the immune response is actively suppressed, and
inflammatory cells contribute in a variety of ways to tumor progression.
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INTRODUCTION
The presence of dense desmoplastic stroma is one of the defin-
ing characteristics of PDAC (Neesse et al., 2010). PDAC stroma
consists of mesenchymal cells such as fibroblasts and pancre-
atic stellate cells (PSCs); ECM proteins including proteoglycans,
fibronectin, and collagens I and III; peri-tumoral nerve fibers;
endothelial cells and cells of the immune system (Korc, 2007;
Farrow et al., 2008). The resulting microenvironment contributes
to cancer initiation, tumor progression (Hwang et al., 2008;
Vonlaufen et al., 2008; Whiteside, 2008; Polyak et al., 2009) and
chemoresistance (Olive et al., 2009; Grippo and Tuveson, 2010).
Inflammatory cells have been linked to tumor development
and progression through their mediation of the inflammatory
response critical for tumor formation from precancerous lesions
(de Visser et al., 2006). In the case of PDAC, a notably higher
incidence of cancer is found in patients with the inflammatory
condition, chronic pancreatitis (CP; Lowenfels et al., 1993; McKay
et al., 2008). Moreover for individuals with hereditary pancreati-
tis, the cumulative lifetime risk (to 70 years of age) of pancreatic
cancer is very high, at 40% (Vitone et al., 2005). In genetically
modified mouse models of PDAC, cerulein-induced pancreati-
tis is known to accelerate the development of PDAC (Guerra
et al., 2007, 2011; Morris et al., 2010). Moreover, pancreatitis
may also hasten the process of metastasis (Rhim et al., 2012).
Using a mouse model of pancreatic cancer in which pancre-
atic epithelial cells could be tracked, Rhim et al. (2012) recently
made the surprising observation that pancreatic cells, in the early
stages of transformation, entered the bloodstream. Interestingly,
the number of circulating pancreatic cells was increased in mice
following the induction of pancreatitis, and treatment with the
anti-inflammatory, dexamethasone, blocked dissemination.
The relationship between tumor cells and the immune sys-
tem is complex. Infiltrations of cells from both the innate and
the adaptive immune systems have been observed in many tumor
types and, depending on their nature, have been linked to prog-
nostic outcome (Pages et al., 2010; Roxburgh and McMillan,
2011) and response to treatment with conventional chemother-
apies (Fridman et al., 2011). One of the hallmarks of cancer is
the need for tumors to evade immune destruction (Hanahan
and Weinberg, 2011), and yet equally important in many cases
is the necessity of the tumor to hijack inflammatory components
of the immune response to create an environment that fosters
tumor growth and progression (Farrow et al., 2008; Hanahan and
Weinberg, 2011).
In this review we focus on the inflammatory components of
pancreatic stroma that contribute to immune suppression, tumor
cell growth and invasion. The negative growth effects of cellu-
lar components, such as cytotoxic T lymphocytes, natural killer
(NK) and dendritic cells, along with their potential exploitation
in the development of immunotherapies are reviewed elsewhere
(Koido et al., 2011; Vanneman and Dranoff, 2012; Wachsmann
et al., 2012). The role of specified inflammatory cells in PDAC are
detailed below and summarized in both Figure 1 and Table 1.
MAST CELLS
Mast cells are associated with allergic and anaphylactic reac-
tions and contribute to immune responses to microbial infection
(Gilfillan and Beaven, 2011). Other functions include facilitating
tissue remodeling and repair following injury, tumor repression
and tumor growth (Gilfillan and Beaven, 2011). Mast cells pro-
duce and secrete potent angiogenic molecules, and have been
implicated in angiogenesis in various malignancies, including
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FIGURE 1 | Inflammatory cell infiltration promotes growth and invasion
in pancreatic cancer. Desmoplastic stroma accumulates as tumorigenesis
progresses, increasing vascular formation and the production of collagen
while recruiting cells of the immune system to enhance tumor growth. Mast
cells and activated tumor associated macrophages (TAMs) localize at the
leading edge of the tumor where they can accelerate tumor invasion, and
TAMs are thought to enhance lymphatic metastasis and angiogenesis.
Myeloid derived suppressor cells (MDSCs), likewise, accumulate at the
invasive front and inhibit CD8+ cytotoxic T cells, enabling immune evasion.
Regulatory T cells (Tregs), which also suppress immune function, can be
found in relatively high abundance in pancreatic ductal adenocarcinoma
(PDAC). The presence of Th2 T helper cells in greater numbers than Th1 has
also been linked to increased tumor growth. PanIN = Pancreatic
intraepithelial neoplasia.
laryngeal squamous cell carcinomas, lung cancers and malignant
melanomas (Norrby, 2002). As tumors develop, mast cell precur-
sors are attracted to the tumor stroma. They express the receptor
for stem cell factor (KIT) and tumor-derived stem cell factor is
believed to cause the recruitment and activation of mast cells
in tumors (Ribatti and Crivellato, 2011). Once activated, mast
cells release inflammatory factors such as interleukin-6 (IL-6),
tumor necrosis factor-α, and vascular endothelial growth factor
(VEGF; Ribatti and Crivellato, 2011). Through the secretion of
immunosuppressive cytokines such as IL-10, mast cells down-
regulate the immune response to tumors (Ribatti and Crivellato,
2011). They also favor expansion and activation of regulatory
T (Treg) cells which promote immune tolerance (Ribatti and
Crivellato, 2011).
In a transgenic mouse model of pancreatic cancer which
expresses high levels of mutant K-ras (KRasG12V ), PDAC was
associated with an influx of mast cells (Chang et al., 2011). In
this model, mast cells were evenly distributed in CP and pancre-
atic intraepithelial neoplasia (PanIN) lesions, whereas they were
observed at the infiltrating edges of tumor. To determine the
effects of mast cells on PDAC growth, pancreatic tumors were
grown orthotopically in mast cell-deficient mice (Kit−/− mice).
PDAC growth was significantly reduced in Kit−/− mice com-
pared to control mice, and the mast cell-deficient mice lived
longer. These findings matched those in human tissues from
patients with PDAC (n = 67), in which higher levels of mast cells
corresponded with poor outcome, corroborating a trend seen
in a previous study (Esposito et al., 2004). More recently, high
mast cell counts in the cancerous border with normal tissue were
linked to poor prognosis (Cai et al., 2011). In vitro studies have
indicated that there may be cross-talk between mast cells and
PDAC cells. One study noted that signals secreted from PDAC
cells stimulated mast cell migration whilst reciprocating signals
selectively increased proliferation of tumor cells (Strouch et al.,
2010). Furthermore mast cells were found to promote the inva-
siveness of pancreatic tumor cells in a matrix metalloproteinase
(MMP)-dependent manner (Strouch et al., 2010).
The observation of mast cell infiltration in CP and PanIN
lesions in KRasG12V mice (Chang et al., 2011), suggests that
recruitment of mast cells may occur early in the development of
pancreatic cancer and is consistent with the notion of inflamma-
tion potentiating neoplasia. It is likely that mast cells are involved
in signaling with other components of the tumor microenvi-
ronment as part of the overall inflammatory response. IL-33 is
known to activate mast cells and stimulate pro-inflammatory
cytokine production (Xu et al., 2008), and has been found to
be expressed in the nuclei of activated PSCs (Masamune et al.,
2010). Similarly, mast cell tryptase contained within mast cell
granules and released upon degranulation has been found to
stimulate hepatic stellate cell proliferation and collagen produc-
tion, an essential process in stromal formation (Gaça et al., 2002).
With the notable presence of mast cells in the stroma of PDAC
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Table 1 | Summary of the role of specified inflammatory cells in pancreatic cancer.
Inflammatory cell Relevance to PDAC Reference
Mast cell (MC) • MC counts in human PDAC cancer edge linked to poor prognosis Cai et al., 2011
• MCs observed at the infiltrating edges of pancreatic tumors in mice Chang et al., 2011
• PDAC tumor growth reduced and survival increased in MC-deficient mice
Myeloid-derived
suppressor cell
(MDSC)
• MDSC levels are elevated in peripheral blood of cancer patients (including
PDAC patients) compared to controls. The risk of death was increased as the
percentage of MDSCs increased
Gabitass et al., 2011
• MDSCs infiltration of pancreatic tumors in genetically modified mice is
accompanied by a lack of T cells, especially CD8+ cytotoxic T cells
Clark et al., 2007
Tumor associated
macrophage (TAM)
• M2-polarised TAMs (CD163 or CD204-positive macrophages), but not CD68-
positive macrophages, associated with a poor prognosis linked to
accelerated lymphatic metastasis
Kurahara et al., 2011
• SPARC positively influences the infiltration and the distribution of
macrophages to pancreatic tumors in mice
Puolakkainen et al., 2004
• TAMs recruited to orthotopic pancreatic tumors in mice express VEGF
receptor 2, which is involved in macrophage recruitment to these tumors
Dineen et al., 2008
• The interaction of macrophage inflammatory protein-3α and chemokine
receptor 6 (CCR6) is proposed to increase PDAC cell proliferation, migration
and invasion
Kimsey et al., 2004; Campbell et al., 2005
• CD40 activation in pancreatic cancer re-established tumor immune
surveillance by targeting macrophages, resulting in the destruction of the
tumor stroma
Kleeff et al., 1999; Beatty et al., 2011
T cell • Regulatory T cells (Tregs) are elevated in the blood of PDAC patients and
correlated with the numbers of MDSCs
Gabitass et al., 2011
• Tregs numbers increase with PanIN progression and advancing grade of
PDAC
Hiraoka et al., 2006
• Elevated ratio of Th2 to Th1 T helper cells is associated with poor prognosis
in PDAC
de Monte et al., 2011
Neutrophil • Significant tumor-infiltrating neutrophils are uncommon in PDAC Reid et al., 2011
Only a selection of published data are presented here.
it will be interesting to elucidate their full contribution to the
pancreatic cancer tumor microenvironment and to PDAC cells
directly.
MYELOID-DERIVED SUPPRESSOR CELLS
A number of different myeloid-derived cells feature within tumor
stroma, including myeloid-derived suppressor cells (MDSCs),
tumor-associated macrophages (TAMs), and dendritic cells.
These cells and their ability to suppress the tumoral immune
response, either alone or through communication with each
other, are reviewed by Ostrand-Rosenberg et al. (2012). MDSCs
are immature myeloid cells that enhance tumor growth by pro-
moting angiogenesis and by suppressing components from both
the innate and the adaptive immune system (Ostrand-Rosenberg
and Sinha, 2009; Ochando and Chen, 2012). They are elevated in
both the circulation and the tumor microenvironment of patients
with cancer, and comprise two main subsets, a monocytic sub-
population expressing CD14 and a granulocytic subpopulation
expressing CD15 (Ostrand-Rosenberg et al., 2012). MDSCs use
a variety of mechanisms to actively suppress host immunity such
as inhibition of T-cell activation, through the production of reac-
tive oxygen (Kusmartsev et al., 2004) and nitrogen species and
the depletion of the amino acids arginine and L-cysteine; inhibi-
tion of T cell migration; expansion of immunosuppressive Tregs
and inhibition of NK cell cytotoxicity (Ostrand-Rosenberg et al.,
2012).
In a genetically modified mouse model of pancreatic can-
cer, in which oncogenic KRasG12D is expressed in a pancreas-
specific fashion, the analysis of immune cells during pancreatic
cancer progression (Clark et al., 2007) revealed a slight eleva-
tion in the number of MDSCs in PanIN lesions, giving way
to a more pronounced increase in PDAC. MDSCs accumu-
lated around periductal areas and stroma in PDAC, although
their infiltration was delayed compared to macrophages (Clark
et al., 2007). Interestingly, the presence of MDSC infiltrates was
accompanied by a lack of T cells, especially CD8+ cytotoxic
T cells. This is consistent with previous work which demon-
strated that MDSCs inhibit the CD8+ T cell response through
the production of reactive oxygen species (Kusmartsev et al.,
2004). The inhibitory effect of MDSCs on CD8+ T cells was fur-
ther supported by a recent study in which murine pancreatic
cancer cells (Panc02) were inoculated into immunocompetent
mice (Pilon-Thomas et al., 2011). Tumor-bearing mice exhibited
down-regulation of src homology 2 domain-containing inosi-
tol 5’-phosphatase-1 (SHIP-1) expression in splenocytes, and an
expansion of MDSCs in the peripheral blood and splenocytes.
MDSCs from tumor-bearing mice overexpressed Bcl-2, contained
hyper-phosphorylated Akt (Pilon-Thomas et al., 2011) and were
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found to suppress CD8+ T cell growth to a greater extent than
MDSCs from control mice (Pilon-Thomas et al., 2011).
In a study of patients with pancreatic (n = 46), oesophageal
(n = 60) and gastric (n = 25) cancers, both Treg and MDSC
(HLADR− Lin1low/− CD33+ CD11b+) levels were found elevated
in peripheral blood of cancer patients compared to 54 healthy
controls (Gabitass et al., 2011). The risk of death was increased
as the percentage of MDSCs increased (Gabitass et al., 2011).
Recently, a mechanism of tumor invasion has been identified
where MDSCs alter the structure of MHC class I expressed on the
tumor cell surface, preventing the binding of processed peptide
that would otherwise activate antigen-specific CD8+ T cells (Lu
et al., 2011). This process was linked to the production of perox-
ynitrite (PNT), the predominant source of which, in pancreatic
cancer patients, was myeloid cells.
MACROPHAGES
Macrophages normally fight infection, facilitate wound heal-
ing and regulate tissue homeostasis. They localize to sites of
inflammation by responding to the chemoattractant, monocyte
chemotactic protein 1 (MCP-1; Farrow et al., 2008), and act as
one of the crucial effectors of the inflammatory response, releas-
ing cytokines, and growth factors (Coussens and Werb, 2002).
Their presence in the microenvironment of tumors has prompted
analysis of their role in cancer (reviewed in Ostrand-Rosenberg
et al., 2012; Ruffell et al., 2012). TAMs possess a number of char-
acteristics that facilitate tumor growth and support metastasis.
Through the production of vascular endothelial growth factor A
(VEGFA), they contribute to angiogenesis; by producing compo-
nents of ECM, such as collagens and ECM degrading enzymes,
such as MMPs, they contribute to stromal remodeling and to
cell migration within the tumor (Ostrand-Rosenberg et al., 2012;
Ruffell et al., 2012). Macrophages are classified into two extreme
phenotypic types, pro-inflammatory M1 macrophages and anti-
inflammatory M2 macrophages, although in reality the pheno-
type of macrophages is complex and cannot be fully explained by
a simple division into two discrete groups. M1-like macrophages
promote tumor cell death, while M2-like macrophages favor
tumor progression (Ostrand-Rosenberg et al., 2012; Ruffell et al.,
2012).
An assessment of TAMs in PDAC tumors, using the common
macrophage marker, CD68 as well as markers specific for recep-
tors on M2-polarised macrophages, CD163 and CD204, found
that the presence of high numbers of M2-polarised macrophages
correlated with a high incidence of lymph node metastasis.
Moreover, high lymphatic vessel density, as measured using
D2–40, and poor prognosis were observed in cases with high
number of CD163 or CD204-positive macrophages, but not
CD68-positive macrophages (Kurahara et al., 2011).
A number of mechanisms have been proposed for the
recruitment and activity of macrophages in pancreatic tumors.
Macrophage inflammatory protein-3α (Mip-3α) is expressed in
PDAC and mononuclear inflammatory cells in PDAC patient
tissues (Kimsey et al., 2004; Campbell et al., 2005). Specific inter-
actions of Mip-3α and its receptor, chemokine receptor 6 (CCR6)
which is expressed in PDAC cells, have been shown to increase
PDAC cell proliferation, migration and invasion in type IV
collagen, possibly through upregulation of MMP-9 production in
the tumor cells (Kleeff et al., 1999; Kimsey et al., 2004; Campbell
et al., 2005). Similarly, a role for VEGF has been elucidated. VEGF
is one of several cytokines to mediate macrophage recruitment
to tumors. Dineen et al. (2008) demonstrated the expression of
VEGF receptor 2 on TAMs of orthotopic pancreatic tumors in
mice. Selective inhibition of this receptor diminishedmacrophage
infiltration into these tumors. Focal adhesion kinase (FAK), a
known regulator of cell migration, proliferation, apoptosis, and
survival, has also been implicated in enabling macrophage infil-
tration in PDAC (Stokes et al., 2011). Interestingly, an intracellu-
lar matrix protein, the matricellular glycoprotein secreted protein
acidic and rich in cysteine (SPARC) has been shown to influence
the infiltration and the distribution of macrophages to pancre-
atic tumors in mice. Panc02 cells were grown subcutaneously
in SPARC-null and wild-type SPARC mice. F4/80-expressing
murine macrophages were more plentiful in tumors from wild-
type mice, and were distributed at the margins of tumors. By
contrast in SPARC-null mice, the distribution of macrophages
was even throughout the tumors (Puolakkainen et al., 2004).
Other mechanisms underpinning the actions of macrophages
in pancreatic cancer have also been suggested. TAMs were found
to produce Sonic hedgehog (Shh) upon stimulation of the NF-
κB pathway, causing an increase in PDAC cell proliferation, while
IL-1β release from stimulated macrophage cells was shown to
protect PDAC cells from drug-induced apoptosis by upregulat-
ing cyclooxygenase 2 (COX-2) production (Angst et al., 2008;
Yamasaki et al., 2010).
T CELLS
CD3+ T lymphocyte infiltrations have been reported in both
human and mouse PDAC tissue specimens (von Bernstorff et al.,
2001; Clark et al., 2007). Studies have focused on the presence and
function of CD4+ CD25high T regulatory cells (Tregs; Hiraoka
et al., 2006; Gabitass et al., 2011). Like MDSCs, Tregs display
an immunosuppressive phenotype, and are important mediators
of immune evasion in cancer. The mechanisms used by Tregs to
suppress immune function, including the suppression of CD4+
CD25− conventional T cells, are reviewed elsewhere (Menetrier-
Caux et al., 2012; Schmidt et al., 2012). As stated already in this
article, the numbers of both Tregs (CD4+ CD25+ CD127low/−
FoxP3+) and MDSCs were found to be elevated in the circula-
tion of pancreatic cancer patients and correlated with one another
(Gabitass et al., 2011). CD4+ FoxP3+ Tregs have been identi-
fied in PDAC tissues in significantly higher quantities than in
non-neoplastic inflammatory pancreatic stroma (Hiraoka et al.,
2006). Moreover, higher levels of Tregs corresponded with more
poorly differentiated tumors. Similarly, analysis of progressive
grades of PanIN revealed a significant increase in the prevalence
of Tregs from low-grade PanIN to invasive ductal carcinoma, with
a corresponding decrease in CD8+ T cell infiltration with PanIN
progression. High tumoral Treg levels were associated with poor
prognosis (Hiraoka et al., 2006).
Possible mechanisms for the increase in abundance of Tregs in
the tumor microenvironment have been demonstrated in mouse
models. Panc02 cells inoculated into a murine host were shown to
secrete chemokine (C-C motif) ligand 5 (CCL5; Tan et al., 2009)
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and transforming growth factor-β (TGF-β; Moo-Young et al.,
2009) resulting in the recruitment of Tregs or the conversion of
CD4+ CD25− naive T cells into Tregs (Moo-Young et al., 2009).
Along with Tregs, T helper (Th) cells have also been stud-
ied in PDAC, though the literature on the subject is limited.
Th cells activate cells of the innate immune system, facilitate
wound repair and provide assistance to B cells and cytotoxic
CD8+ T cells (O’Shea and Paul, 2010; Okoye and Wilson, 2011).
Several subsets of Th cell exist including Th1 cells that produce
interferon-γ (IFN-γ) and induce microbial elimination, and Th2
cells that secrete IL-4 and IL-13 and are thought to mediate
helminth immunity (Abbas et al., 1996; O’Shea and Paul, 2010).
Immunohistochemical analyses of PDAC samples have revealed
the presence of both Th1 and Th2 cell populations, with evidence
that the quantity and activity of Th cells are skewed toward the
Th2 subset (Bellone et al., 1999; Tassi et al., 2008). A recent study
reported that the ratio of Th2 GATA-3+ to Th1 T-bet+ cells is
an independent predictor of disease-free and overall survival in
PDAC patients, suggesting a link between Th2 prevalence and
tumor progression (de Monte et al., 2011). The authors propose
a mechanism whereby tumor cells induce the release of thymic
stromal lymphopoietin (TSLP) from cancer-associated fibrob-
lasts (CAFs) which subsequently activates tumor antigen-loaded
dendritic cells. They posit that dendritic cells then migrate and
activate tumor antigen-specific Th2 cells at the draining lymph
nodes. The activated Th2 cells then home to the tumor site and
may promote tumor growth (de Monte et al., 2011). This study
illustrates the important cross-talk between components of the
stroma and the immune system.
NEUTROPHILS
Neutrophils play crucial roles in defense against infectious dis-
eases, act as early modulators of inflammation and are often
the initial recruited effector at sites of acute inflammation. They
are key regulators of the immune response (Kumar and Sharma,
2010; Mantovani et al., 2011).
A recent systematic analysis of tumor infiltrating neutrophils
was undertaken in a variety of pancreatic neoplasms (Reid et al.,
2011). The authors defined 10 or more infiltrating neutrophils
per 100 epithelial cells as positive, and classified more than
15 tumor-infiltrating neutrophils as significant. Significant neu-
trophil infiltrates were rarely found in PDAC, but were observed
in micropapillary and undifferentiated types of poor prognosis.
In PDAC, an elevated pre-operative neutrophil-lymphocyte
ratio (NLR) was reported to be associated with poor progno-
sis, contrasting with platelet-lymphocyte ratio, which showed no
relationship with outcome (Bhatti et al., 2010). The prognostic
value of NLR was verified in an independent study (Wang et al.,
2012) and is consistent with observations made in other malig-
nancies (Walsh et al., 2005; Gomez et al., 2008; Cho et al., 2009;
Sarraf et al., 2009).
CONCLUDING REMARKS
Cancer cells express tumor antigens and can elicit an immune
response. Unfortunately, tumors also develop mechanisms
enabling themselves to escape immune surveillance. Hiraoka
et al. (2011) recently investigated the host immune response in
intraductal papillary mucinous neoplasm (IPMN), a precursor
lesion that can lead to pancreatic cancer. The adenoma stage
(IPMA) was characterized by an antitumor immune response.
However, the immune reaction changed to immune tolerance
in the carcinoma stage (IPMC). Inflammatory cells can con-
tribute to tumorigenesis through immune suppression. They
also facilitate cancer progression by promoting angiogenesis and
facilitating cancer metastasis. Our review has focused on the
tumor-promoting effects of inflammatory cells, as opposed to
the anti-tumoral effects of inflammatory cells. Although good
progress has been made in understanding how inflammatory cells
support tumor growth, a great deal of research is still necessary
before we fully appreciate the tumor promoting roles of these cells
in PDAC.
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